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Human asthma is a complex and heterogeneous disorder characterized by chronic inflammation, 
bronchospasm and airway remodeling. The latter is a major determinant of the structure-function 
relationship of the respiratory system and is likely contributing to the progressive and accelerated 
decline in lung function observed in patients over time. Anti-inflammatory drugs such as 
corticosteroids are the cornerstone of asthma treatment. While their action on inflammation and 
lung function is well characterized, their effect on remodeling remains largely unknown. An 
important hindrance to airway remodeling as a major focus in asthma research is that the 
physiologic and clinical consequences of airway wall thickening and altered composition are not 
well understood. In this perspective, equine asthma provides a unique and ethical (non-terminal) 
preclinical model for hypothesis testing and generation. Severe equine asthma is a spontaneous 
disease affecting adult horses characterized by recurrent and reversible episodes of disease 
exacerbations. It is associated with bronchoalveolar neutrophilic inflammation, bronchospasm, 
excessive mucus secretion. Severe equine asthma is also characterized by bronchial remodeling, 
which is only partially improved by prolonged period of disease remission induced by therapy or 
antigen avoidance strategies. This review will focus on the similarities and differences of airway 
remodeling in equine and human asthma, on the strengths and limitations of the equine model, and 
on the challenges the model has to face to keep up with human asthma research. 
 





Human asthma is a complex and heterogeneous disorder that affects over 334 million people 
worldwide; its prevalence is estimated to increase in the coming years, especially in low-income 
countries. It is a chronic inflammatory condition whose main clinical trait is a variable and (at least 
partially) reversible respiratory obstruction (Papi, et al., 2018). Another important feature of human 
asthma, first described in the early 20’s (Huber and Koessler, 1922), is airway remodeling. This 
terminology describes a well-characterized set of changes in structural cells and tissues of the 
airways (Hirota and Martin, 2013), but whose impact on asthma clinical presentation is largely 
unknown (Prakash, et al., 2017). In this review we discuss the potential contribution of the equine 
model of asthma to this unsolved issue.  
 
Airway remodeling  
Morphological and/or phenotypic alterations are reported for all the structural cell types in the 
bronchi of asthmatic patients. Overall, the remodeled airways are thickened, mainly as a 
consequence of the increased deposition of submucosal extracellular matrix and of the increased 
airway smooth muscle mass. Also, the airway lumen is often reduced as a result of the increased 
secretion of mucus from the epithelium and submucosal glands. Asthma-associated traits of airway 
remodeling are typically described as subepithelial fibrosis, increased smooth muscle mass, gland 
enlargement, neovascularization and epithelial alterations (Bergeron, et al., 2010). The same traits 
are recognized in the airways of asthmatic horses (Figure 1).  
Remodeling is generally considered as the consequence of chronic tissue inflammation and 
dysregulated repairs. However, the similar degree of remodeling observed in recent compared to 
long-standing mild asthmatic patients (Boulet, et al., 2000), the demonstration of bronchial 
remodeling in wheezing children (O'Reilly, et al., 2013, Saglani, et al., 2007), and the rapid 
remodeling response observed after antigen challenges in asthmatics (Kariyawasam, et al., 2007) 
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argue against a chronic insult being necessary for the development of all alterations found in human 
asthmatic airways. The results of a recent study showing increased collagen deposition below the 
basement membrane occurring rapidly in response to methacholine challenges in asthma patients 
also questions the need of (eosinophilic) inflammation in this process, at least once the disease has 
already developed/is already present (Grainge, et al., 2011). Collectively, these data support the 
theory that, albeit intimately linked, inflammation and remodeling maintain a certain degree of 
independence, most likely due to the fact that they can be regulated by separate pathways, and 
affecting different cell-types. Current knowledge on this matter is limited as most of the research 
has focused only on the inflammatory side, with a few glimpses on remodeling. Studying airway 
inflammation and remodeling in parallel and using a systematic approach might provide the much-
needed information on the overlap and interdependence of asthma pathogenetic pathways.       
Airway remodeling is a major determinant of the structure-function relationship of the respiratory 
system (West, et al., 2013). It significantly contributes to airflow obstruction in asthma, particularly 
during episodes of acute bronchoconstriction (asthma exacerbations). However, the relationship 
between airway structure and its function (meaning, how well/smoothly the air can pass/flow 
through the tube) is not a linear one (Jarjour, et al., 2012). In fact, airway remodeling has qualitative 
aspects as well (i.e. altered stiffness of the extracellular matrix, heterogeneous airway smooth 
muscle contraction), whose quantification is hard to achieve, and which perturb the system in a less 
predictable way. There is also evidence of a variable effect of asthma (and of diverse phenotypes of 
asthma) at different levels of the bronchial tree. To complicate matters further, the structure-
function relationship of the respiratory system physiologically changes along the bronchial tree and 
with aging, even in healthy people (James and Carroll, 2000, Thannickal, et al., 2015). 
As a result, asthma alters the physiologic structure-function relationship of the aging human lung, 
leading to an accelerated decline of airway function (Lange, et al., 1998, Lange, et al., 2006). The 
major determinant of this accelerated decline in asthmatic patients remains undetermined, however. 
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Indeed, although it is tempting to speculate that airway remodeling is the most plausible cause for 
the loss of lung function observed in asthma, recent reports suggest that only inflammation and 
acute exacerbations are likely to play a role in this process (Bai, et al., 2007, Coumou, et al., 2018, 
Newby, et al., 2014, Ortega, et al., 2018), disregarding the effect they are likely to have on 
remodeling.   
  
Airway remodeling as a major focus in human asthma research 
Asthma-associated airway remodeling has gained importance only in the last decades (Boulet and 
Sterk, 2007). Up to now and to the best of our knowledge, however, it has never been listed among 
the primary outcomes of randomized clinical trials for testing the efficacy of asthma treatment. Due 
to technical and economic constraints, most of our understanding of the putative determinants and 
impact of airway remodeling on the clinically relevant outcomes of human asthma derives from 
small-to-medium size observational cross-sectional studies. Nevertheless, this approach has 
significantly increased our understanding of “what remodeling is” and, albeit only partly, of “how 
remodeling changes in different asthma phenotypes”; but still leaves unanswered the questions on 
“what causes remodeling” and on “what remodeling does”. An official research statement by the 
American Thoracic Society details the challenges hindering research and therapeutic advances 
concerning our understanding on airway remodeling (Prakash, Halayko, Gosens, Panettieri, 
Camoretti-Mercado, Penn, Structure and Function, 2017). It underlines that the limited 
understanding of the physiologic and clinical consequences of airway wall thickening in asthma has 
prevented the study of airway remodeling as a major focus in human asthma research. 
Understanding airway remodeling mechanisms and their impact on disease is the key toward the 
development of anti-remodeling therapies. To date, airway remodeling is thought to be minimally 
affected by current treatments (Prakash, Halayko, Gosens, Panettieri, Camoretti-Mercado, Penn, 
Structure and Function, 2017), but the data available is too scarce and heterogeneous to draw 
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reliable conclusions on this matter. While there is no doubt that human tissues are the gold standard 
to study the implications of airway remodeling in human asthma, it is ethically and economically 
unconceivable to obtain (repeated) airway biopsies, especially from the peripheral airways, from 
such a high number of patients as it would be necessary in order to study all the possible factors 
implicated in these processes. Also, while imaging modalities such as multidetector computed 
tomography (CT) and magnetic resonance imaging with hyperpolarized helium (He
3
) might have a 
role in quantifying airway thickness, they do not provide sufficient detail to study remodeling, 
especially when studying the small peripheral airways. In this perspective, animal models are 
unavoidable resources, but a mindful approach is necessary, given the limited understanding of the 
triggering factors responsible for the development of airway remodeling in human asthma. 
 
Measures of efficacy of human asthma treatment  
Asthma may be transient is some patients, especially when developing during childhood. However, 
due to the chronic nature of the disorder and to the unavailability of curative therapies, most asthma 
patients are doomed to lifelong pharmacologic treatment in order to maintain airway patency and 
adequate respiratory airflow. Besides lung function, other clinical outcomes of asthma that have 
gained importance in the last years to assess the efficacy of new therapeutic approaches are 
blood/bronchial inflammation, exacerbation rate, asthma control, and the corticosteroid 
maintenance daily dose (only when assessing add-on or biological treatments, and non-
pharmacological interventions). Inflammation in trials for asthma therapies refers mostly to 
eosinophilic inflammation, either in the blood or in the airways. This outcome appears to work well 
for those treatments directed towards the T-2/Th-2 pathways (Bhakta and Woodruff, 2011, Fahy, 
2015, Fajt and Wenzel, 2015, Ingram and Kraft, 2012), while it might reveal inadequate for 
neutrophilic patients. The exacerbation rate defines how frequently the patient sustains acute 
deterioration of its clinical status (due to an obstructive event) requiring the attention of the 
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attending clinician and/or intensive care unit access/hospitalization/intubation within an interval of 
time (Fuhlbrigge, et al., 2012, Reddel, et al., 2009). Asthma control is a questionnaire-based 
measure that aims to quantify how much the daily activities of a patient are affected by asthma-
associated symptoms (it can be viewed as a proxy of the quality of life). Of note, unlike other 
measures of asthma control, neutrophilic inflammation and asthma exacerbation rate appear to be 
less responsive to corticosteroid treatment, the pillar of asthma therapeutic approach (Harrison, et 
al., 2004, Jatakanon, et al., 1999, Macedo, et al., 2009, Moore, et al., 2014, Oborne, et al., 2009, 
Roy and Milgrom, 2010). It is tempting to speculate that thickened airways are more prone to more 
frequent acute obstruction, as partly supported by studies finding a positive association between 
increased wall thickness and disease severity (Bai, 2010, Montaudon, et al., 2009, Niimi, et al., 
2004), but this relationship remains speculative.  
Given its high prevalence and the chronicity of its treatment, human asthma is associated with high 
healthcare costs. Moreover, the majority of asthma-related costs address the needs of a small subset 
of patients with the severe form of the disease (O'Neill, et al., 2015), which is associated with a 
pronounced airway remodeling (Aikawa, et al., 1992, Benayoun, et al., 2003, James, et al., 2009, 
James, et al., 2012). In this perspective, understanding whether and how airway remodeling 
influences the clinical outcome employed to assess the efficacy of asthma treatments is paramount.  
 
An oversimplification of asthma 
Clinically, asthma shows as a combination of the clinical outcomes listed in the previous paragraph.  
Any of these outcomes of asthma, or even their sum, can be seen simplistically as: 
𝐴𝑠𝑡ℎ𝑚𝑎 = 𝑘 + 𝑖𝑛𝑓𝑙𝑎𝑚𝑚𝑎𝑡𝑖𝑜𝑛 + 𝑟𝑒𝑚𝑜𝑑𝑒𝑙𝑖𝑛𝑔 + 𝐴𝑆𝑀 𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 
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Where k represents the reference population data (and its genetic variability) and asthma stands for 
the sum of the clinical outcomes associated with this disorder. Obviously, this model does not take 
into account time, the complex interactions between these parameters, or the latency of effect of any 
of the factors included. Also, genetic factors that might affect inflammation, remodeling, or ASM 
activation are not explicitly reported; and the effects of smoke exposure, aging, and comorbidities 
are disregarded. However, it is deliberately written in these terms to focus on the single component 
causes of the basic causal mechanism of asthma. It is worth noting that, in this view, the treatment 
is included in the term “asthma”, but the equation can be rewritten as: 
𝐴𝑠𝑡ℎ𝑚𝑎 = (𝑘 + 𝑖𝑛𝑓𝑙𝑎𝑚𝑚𝑎𝑡𝑖𝑜𝑛 + 𝑟𝑒𝑚𝑜𝑑𝑒𝑙𝑖𝑛𝑔 + 𝐴𝑆𝑀 𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛) − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
Given that most asthma treatments act on several pathways, it makes sense to break up the effect of 
treatment into several terms: 
𝐴𝑠𝑡ℎ𝑚𝑎 = (𝑘 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) + (𝑖𝑛𝑓𝑙𝑎𝑚𝑚𝑎𝑡𝑖𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) + (𝑟𝑒𝑚𝑜𝑑𝑒𝑙𝑖𝑛𝑔 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
+ (𝐴𝑆𝑀 𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) 
Thus, as (k-treatment) is the effect of treatment on healthy people and it is likely to be equal to k: 
𝐴𝑠𝑡ℎ𝑚𝑎 = 𝑘 + (𝑖𝑛𝑓𝑙𝑎𝑚𝑚𝑎𝑡𝑖𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) + (𝑟𝑒𝑚𝑜𝑑𝑒𝑙𝑖𝑛𝑔 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
+ (𝐴𝑆𝑀 𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) 
Where (inflammation – treatment) is the effect of the treatment on asthma-related inflammation; 
(remodeling – treatment) is the effect of the treatment on asthma-related airway remodeling; and 
(ASM activation – treatment) is the effect of treatment on asthma-related bronchoconstriction.  
Ideally, in order to study the specific effect of airway remodeling on the clinical outcomes of 
asthma, a model (or a treatment) where inflammation and ASM activation could be modulated and, 
possibly, nullified, would be required. While this cannot be achieved in toto in human patients or in 




Animal models of asthma 
 Animal models of asthma can be classified as models of induced disease, genetically manipulated 
models, and spontaneous models (Rosenberg and Druey, 2018). The animal model used is selected 
based on the research question to be addressed. Mouse models (either challenge-induced disease or 
genetically manipulated) are commonly studied in asthma research due to their convenience and 
contained costs. They are well suited for genetic manipulations when the aim of the study is 
biomechanistical. However, their appropriateness for translational research is more limited. This is 
due mainly to anatomical and physiological differences between mice and men, likely affecting at 
least some of the outcomes most frequently studied. Indeed, mice bronchial tree is less developed 
than in humans, and most of the lung is represented by lung parenchyma (at the expenses of small 
airways). The size of the largest intrapulmonary airway in mice is approximately that of a small 
humans airway (<2 mm in diameter), with important implications for data interpretation. Murine 
airways also lack submucosal glands, as well as a normal intra-pulmonary systemic (bronchial) 
circulation, and have limited airway smooth muscle mass compared to humans (Shin, et al., 2009); 
thus, the study of these features for human asthma research has important limitations. Mice size, 
breathing frequency and respiratory volumes cause their structural cells to undergo very different 
loads and frequency of loads compared to the human ones (Fehrenbach, et al., 2017, Rosenberg and 
Druey, 2018). Given the importance of these factors in human lung physiology, lung function 
results derived from mouse model studies should be interpreted with caution. Second, mice are not 
naturally prone to develop clinical pulmonary conditions associated with inflammation or allergic 
disorders. Thus, the ability to induce asthma-like airway inflammation by allergen challenge in this 
model does not prove our ability to reproduce the complexity of the mechanisms underlying 
spontaneous asthma. As stated by Stephen T. Holgate: «While asthma is an inflammatory disorder 
[…], inflammation itself does not explain the origin(s) of this disease nor why the airways are so 
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susceptible to a range of different environmental factors» (Holgate, 2011). Indeed, even after 
sensitization and allergen-challenge, allergic mice – whose airways are inflamed – do not show 
increased airway resistance unless spasmogens are administered (Rosenberg and Druey, 2018). 
Lastly, it has to be noticed that most remodeling data obtained from asthmatic mice are obtained 
from (boosted) allergic or Th2-‘high’ models, which we now know reflect the status of only a 
portion of asthmatic patients (Douwes, et al., 2002, Woodruff, et al., 2009). Rats show anatomical 
advantages over mice when studying airway remodeling: first, the submucosal and the smooth 
muscle layers are more pronounced in the proximal large airways of rats than mice; second, rats 
possess a bronchial circulation and their mucosa and submucosa are provided with capillaries and 
veins while in mice only the trachea and the first bronchial ramifications have an arterial blood 
supply (Tschernig, et al., 2008). Rats also show an earlier response to an allergen challenge 
compared to mice in terms of airway remodeling (Fehrenbach, Wagner and Wegmann, 2017). 
Different challenges can induce both airway smooth muscle and extracellular matrix remodeling in 
rat airways, making this species adapt to study several aspects of airway remodeling (Martin and 
Tamaoka, 2006). 
In nature, cats, monkeys and horses suffer from spontaneous forms of asthma-like conditions. 
Feline asthma affects approximately 1 to 5% of adult cats and is characterized clinically by 
recurrent episodes of cough, mucus hypersecretion and bronchoconstriction in the presence of 
airway hyperresponsiveness and eosinophilic inflammation (Trzil and Reinero, 2014). A 
disadvantage of the feline model of asthma is the unawareness of the triggers inducing spontaneous 
disease exacerbations. House dust mite and Bermuda grass allergens have been successfully used 
for sensitization and to induce exacerbations and asthma-associated bronchial remodeling both in 
central and peripheral airways in normal cats. However, chronic sensitization appears to blunt the 
eosinophilic response associated with feline asthma (Norris Reinero, et al., 2004), unlike what is 
observed in the spontaneous disease. When used as a model for asthma, monkeys need to be 
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sensitized with these allergens, although spontaneous sensitization to certain allergens such as those 
from Ascaris spp., dust mite and cedar pollen occurs in monkeys. They are a model for human 
allergic asthma, and when challenged for prolonged period of time they also develop remodeling 
features similar to those observed in humans. Their use is however limited by costs and ethical 
issues (Coffman and Hessel, 2005). 
 
Equine asthma, a proxy for human airway remodeling research 
History and definitions 
Equine asthma is a term that encompasses a broad set of terminologies previously employed by 
veterinarians for non-infectious, inflammatory, recurrent (chronic) and reversible disorders of adult 
horses characterized clinically by airflow obstruction associated with a cough, mucus 
hypersecretion and airway hyperreactivity (Figure 2). Equine asthma is now broadly classified as 
mild to severe based on the severity of airway obstruction (and recurrence of the condition). Severe 
asthma (heaves, RAO…) describes a well characterized and clinically recognizable phenotype of 
the disease. Horses with severe asthma are typically 7 years or older (adult), afebrile, with repeated 
episodes of increased respiratory effort at rest, and respond generally to corticosteroid or 
bronchodilator treatment (Leclere, et al., 2011b). Of note, bronchodilator treatments such as beta-2 
adrenergic agonists or anticholinergic drugs, the most commonly used in horses, induce a clinical 
improvement (Calzetta, et al., 2017, Derksen, et al., 1999) but does mask the underlying 
inflammation and might be detrimental in terms of hyperreactivity when chronically administered 
(Bullone, et al., 2017c). Typically, horses with severe asthma have a predominant neutrophilic 
inflammation in their lower airways, which makes of severe asthma a neutrophilic disorder. 
However, some studies have also reported an increase in mast cells and one of their products 
(tryptase) in bronchoalveolar lavage fluid (BALF) of severely asthmatic horses (Dacre, et al., 2007, 
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Leclere, et al., 2011a). Lastly, it has to be emphasized that severe equine asthma should be seen as a 
clinical phenotype or a syndrome, rather than a disorder with a unique etiology. Indeed, at least 2 
groups of etiological agents are able to cause (separately or in conjunction) clinically overlapping 
conditions commonly referred to as severe asthma exacerbations in horses. They are the antigens 
related to hay and straw exposure – typically dusts, mites and LPS (Pirie, et al., 2002, Pirie, et al., 
2003a, Pirie, et al., 2001, Pirie, et al., 2003b) – and those related to seasonal pollens (Bullone, et al., 
2016b, Costa, et al., 2006, Seahorn and Beadle, 1993).  
Mild (to moderate) equine asthma represents a wider phenotype, where all non-infectious 
respiratory conditions causing chronic (>4 weeks) cough, poor performance, and/or 
hyperresponsiveness are gathered together (Pirie, et al., 2016), with blurred boundaries available to 
define pathophysiologically different events (Bond, et al., 2018, Pirie, Couetil, Robinson and 
Lavoie, 2016). Mild to moderate asthma affect horses of all ages, concurrently with increases in 
neutrophil, mast cell, and/or eosinophil counts in BALF. Differently from its human counterpart, 
mild to moderate asthma in adult horses is considered a condition that may be transient (a curable 
condition). Only a small subset of horses with mild asthma will progress to the more severe form of 
the condition, but no studies to date have documented the natural history of equine asthma over 
extended period of time.     
Airway remodeling has been studied systematically only in severe equine asthma, while one recent 
study reported remodeling of the central airways in horses with mild to moderate disease 
(Bessonnat, 2018). Indirect evidence suggests that bronchial remodeling might occur in mild cases 
of equine asthma as well (Ter Woort, et al., 2018).  
 
Defining K in horses 
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Based on the over-simplistic model of asthma reported above, asthma results from the sum of 
inflammation, remodeling and ASM activation over what we expect to be the normal condition of a 
healthy subject with the same characteristics of age, sex, weight… but without asthma. Indeed, it 
has to be acknowledged that, at least for some of the variables used to define human asthma (i.e. 
inflammation or lung function), there is a certain degree of physiological variation due to aging and 
its associated processes, such as oxidative stress, increased rates/prevalence of comorbidities and 
altered structure composition. While this is well described in humans, little or no data are available 
for horses. An important step required for a thoughtful scientific use of this animal model should be 
to characterize what is “normal”. While a few data are available concerning variations in BALF cell 
counts associated with aging (Flaminio, et al., 2000, Hostetter, et al., 2017, Pacheco, et al., 2014), 
there are still conflictual results (Gerber, et al., 2003). Moreover, little is known on the anatomic 
and physiologic changes induced by aging in the equine lung (Bullone, et al., 2017b, Mauderly and 
Hahn, 1982, van Brantegem, et al., 2007). Overall, this indicates that more efforts should be spent 
in this direction in order to maximize the information we might gather from this spontaneous animal 
model of asthma. 
 
Airway remodeling in severe equine asthma 
Descriptive changes in the anatomy and structure of the lungs of asthmatic horses date some 
decades ago and have been confirmed over time (Kaup, et al., 1990a, Kaup, et al., 1990b, Thurlbeck 
and Lowell, 1964, Viel, 1983, Winder, et al., 1989). However, it is in more recent times that these 
alterations have been quantified. This has corroborated the initial observations that the magnitude of 
airway remodeling varies along the bronchial tree, and it is most marked peripherally (airways < 2 
mm in diameter).   
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Most remodeling data collected in asthmatic horses concerns ASM, which is reasonable given its 
importance in disease pathophysiology. The available evidence suggests that ASM mass is 
increased both in central/intermediate and peripheral airways, but this process is more accentuated 
peripherally. Indeed, while an average 50% increase in ASM mass has been reported in central 
airways of asthmatic vs. control horses (Bullone, et al., 2015), up to a 300% increase has been 
reported in small peripheral airways (Herszberg, et al., 2006, Leclere, Lavoie-Lamoureux, Gelinas-
Lymburner, David, Martin and Lavoie, 2011a). Both hyperplasia and hypertrophy of ASM cells are 
likely to contribute to this process (Herszberg, Ramos-Barbon, Tamaoka, Martin and Lavoie, 2006, 
Leclere, Lavoie-Lamoureux, Gelinas-Lymburner, David, Martin and Lavoie, 2011a), but their 
dynamics of occurrence are still not elucidated. Neutrophil-mediated ASM cell proliferation might 
represent one of the mechanisms of increased smooth muscle mass in asthmatic horses (Vargas, et 
al., 2016). A different distribution of extracellular matrix (ECM) components has also been 
described in the ASM layer of large and small airways of horses with severe asthma (Bullone, 
Vargas, Elce, Martin and Lavoie, 2017c), resembling the findings in healthy humans but not in 
asthmatic patients (Araujo, et al., 2008, Yick, et al., 2013). However, no data are available on ASM 
composition of healthy horses to draw any conclusion on the implication of such findings in equine 
asthma pathology. 
Compared to humans, equine asthma is characterized by a less marked ASM remodeling of the 
large/intermediate airways when this is measured in whole airway sections using similar approaches 
in both species (Bullone, Beauchamp, Godbout, Martin and Lavoie, 2015, Elliot, et al., 2015, 
James, Bai, Mauad, Abramson, Dolhnikoff, McKay, Maxwell, Elliot and Green, 2009, James, 
Elliot, Jones, Carroll, Mauad, Bai, Abramson, McKay and Green, 2012). Given the substantial 
contribution of the large airways to total airway resistance (West, 2008), this might explain why 
fatal asthma attacks in horses are not reported. A morphological phenotype of severe asthma has 
been described in a limited number of human patients with ASM remodeling observed only in the 
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small airways and with a reduced use of ICS (Elliot, Jones, Abramson, Green, Mauad, McKay, Bai 
and James, 2015). 
Due to obvious physical and ethical limitations, morphometric assessment of remodeling of whole 
airways requires surgical biopsies, which it is almost impossible for large airways. Instead, the most 
easily applicable tool to assess ASM remodeling in the large airways of living human patients is 
endobronchial biopsy, whose results in terms of ASM remodeling have never been directly 
compared to those measured in post-mortem samples with more accurate methods to the best of our 
knowledge. Although endobronchial biopsy is considered the “gold standard” for the study of 
central airway remodeling, a standardization of the methods to be employed for analysis still lacks 
(Jeffery, et al., 2003) and biological variability is high (James and Carroll, 2000). Moreover, data 
obtained from humans and in horses using different analytical methods do not correlate (Bullone, et 
al., 2014, Labonte, et al., 2008), which should discourage direct and deliberate comparison of 
studies employing different measuring units. 
The extracellular matrix lying within the lamina propria is also altered in severe equine asthma, 
both in the central and peripheral airways (Bullone, Chevigny, Allano, Martin and Lavoie, 2014, 
Setlakwe, et al., 2014). Collagen I and III are abundant in the airways and total collagen content is 
increased the peripheral airways of asthmatic horses (Setlakwe, Lemos, Lavoie-Lamoureux, 
Duguay and Lavoie, 2014). Collagen III is related to tissue distensibility while collagen I is the 
major matrix element that resists tensile stresses. Interestingly, airway collagen was positively 
correlated with pulmonary resistance in asthmatic horses in remission of the disease (Setlakwe, 
Lemos, Lavoie-Lamoureux, Duguay and Lavoie, 2014). Only when combined, collagen I and III 
were increased in peripheral airways of asthmatic horses (Furness, et al., 2010, Setlakwe, Lemos, 
Lavoie-Lamoureux, Duguay and Lavoie, 2014), while no information is available concerning their 
distribution in large airways. Collagen I is increased while collagen III was shown to be decreased 
in human asthmatic peripheral airways, which is indicative of a profibrotic process leading to stiffer 
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and less distensible airways (Brown, et al., 2007, Dolhnikoff, et al., 2009, Wilson, et al., 1993). In 
large human airways, proteoglycans as well as the two forms of collagen are increased in severe 
asthmatic vs. healthy individuals, while differences are less marked or even undetectable between 
mild asthmatics and control subjects (Benayoun, Druilhe, Dombret, Aubier and Pretolani, 2003, 
Chakir, et al., 2003, Chu, et al., 1998, de Kluijver, et al., 2005, Huang, et al., 1999, Minshall, et al., 
1997, Pini, et al., 2007). The increased lamina propria thickness observed in asthmatic horses 
compared to controls is in contradiction with what is described in human asthma, despite the 
increased deposition of ECM elements in humans. Indeed, two studies investigating this parameter 
in asthmatic patients have found a decreased epithelium-smooth muscle distance in occupational 
asthma compared to controls (Sumi, et al., 2007), and in severe compared to moderate asthmatics 
(Pepe, et al., 2005). In the first study, asthmatic patients were in remission from occupational 
asthma (not symptomatic and not taking any treatment) for more than 14 years on average. In the 
second study, severe asthmatics were on higher doses of corticosteroid treatment compared to 
moderate asthmatics. The hypothesis that this could have caused a greater decrease of the lamina 
propria thickness in that group is not supported by in vitro data, however (Jacques, et al., 2010). 
There are no obvious reasons explaining this discrepancy between asthmatic men and horses. A 
selective inward vs. outward growth of the ASM cells might be involved. Alternatively, collagen 
fibers could be more densely packed in asthma (Roche, et al., 1989). Lastly, and as discussed 
below, both remission state and the use of corticosteroids have been shown to nearly normalize the 
collagen content in asthmatic horses (Leclere, et al., 2012b), suggesting that discrepancies between 
the results from equine and human subjects may be due to therapy. 
Differently from human asthma, the basement membrane (or lamina reticularis) is not thickened in 
asthmatic horses, possibly due to the fact that severe equine asthma is not an eosinophilic disease 
(Dubuc and Lavoie, 2014). Basal membrane thickness, indeed, has been repeatedly associated with 
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eosinophilia in human asthma (Grainge, Lau, Ward, Dulay, Lahiff, Wilson, Holgate, Davies and 
Howarth, 2011). 
Elastic fiber deposition is increased almost 4-fold in the peripheral airways of asthmatic horses vs. 
controls, but might be dysfunctional (Setlakwe, Lemos, Lavoie-Lamoureux, Duguay and Lavoie, 
2014). Contrarily, no difference was observed between healthy people and non-fatal asthmatic 
concerning the quantity of elastic fibers in their peripheral bronchial wall. They were increased in 
fatal asthma vs. non-fatal asthma instead (Araujo, Dolhnikoff, Silva, Elliot, Lindeman, Ferreira, 
Mulder, Gomes, Fernezlian, James and Mauad, 2008). Elastic fibers of human asthmatic central 
bronchi were initially described as enlarged (or hypertrophic) and fragmented, but overall not 
increased in quantity compared to healthy subjects (Bousquet, et al., 1996, Gabbrielli, et al., 1994, 
Godfrey, et al., 1995). Also, the alterations observed in the large airways of asthmatics were not 
linked to the severity or duration of asthma (Bousquet, Lacoste et al. 1996). Since then, few studies 
have addressed this question using quantitative approaches, showing a reduced or unchanged 
quantity of elastin in human asthmatic airways most of the time (Reddel, et al., 2012). A recent 
work support the hypothesis that IL-13, a pleiotropic cytokine strongly involved in asthma 
pathogenesis, might be one of the causes of the reduced elastin synthesis in asthmatics (Ingram, et 
al., 2015).  
The bronchial epithelium of asthmatic horses is characterized by an increased expression of a 
genetic variant of secretoglobin 1A1 (SCGB 1A1, Clara cell secretory protein), which also increases 
neutrophil oxidative burst and phagocytosis compared to the classical SCGB 1A1 (Cote, et al., 
2014, Cote, et al., 2012). The increased expression of this genetic variant could be the reason why 
previous work have reported depleted granules in absence of concurrent mucus accumulation in 
these cells in the bronchioles of asthmatic horses (Katavolos, et al., 2009). Also, a reduced quantity 
of ciliated epithelial cells is reported (Kaup, Drommer and Deegen, 1990b). Semi-quantitative 
analyses have provided conflicting results on the number of mucous cells in equine airways 
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(Bullone, et al., 2016a, Lugo, et al., 2006). However, a linear relationship exists between bronchial 
epithelial metaplasia, stored muco-substances and inflammation in this species (Lugo, Harkema, 
deFeijter-Rupp, Bartner, Boruta and Robinson, 2006). 
 
Reversibility of airway remodeling 
Whether airway remodeling is reversible, and, if so, to which extent, remains a matter of debate. 
Data available in human asthma suggest that at least ASM remodeling is not, or not completely, 
reversible with the current pharmacological treatments (namely, corticosteroids and 
bronchodilators) (Girodet, et al., 2016, James, Elliot, Jones, Carroll, Mauad, Bai, Abramson, 
McKay and Green, 2012). However, cohorts of asthmatic have not been prospectively evaluated 
before and after treatment in order to definitely answer this question. Studies investigating the effect 
of biologicals on airway remodeling are lacking. Myocyte hyperplasia, at least in the in large 
airways, has also been consistently identified in asthma in studies in which stereology-based 
approaches were employed (Ebina, et al., 1993, James, Elliot, Jones, Carroll, Mauad, Bai, 
Abramson, McKay and Green, 2012, Woodruff, et al., 2004), suggesting this is a less reversible trait 
compared to hypertrophy, which is less commonly observed in patients with stable disease. This is 
consistent to what is observed in equine severe asthma. Indeed, asthmatic horses, even in remission 
of the disease, have twice as much ASM as that observed in healthy horses in their peripheral 
airways (Leclere, Lavoie-Lamoureux, Gelinas-Lymburner, David, Martin and Lavoie, 2011a). Even 
if repeated studies have proven that ASM mass in horses in remission of the disease is decreased 
(about 30%) compared to what observed during disease exacerbations, it appears that there is a 
portion of ASM remodeling which cannot be reversed by corticosteroid treatment, either alone or in 
association with a bronchodilator (Bullone, Vargas, Elce, Martin and Lavoie, 2017c, Leclere, et al., 
2012a). ASM cell number or proliferation markers did not significantly improve with treatment in 
these same studies, while a rapid (4 weeks) response was observed in terms of reduced cell size, 
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especially in large airways. Of note, however, ASM cell size was greater in large than in small 
airways during severe equine asthma exacerbation, which might have magnified the effect of 
treatment in the large airways. Altogether, these findings suggest that, both in human and equine 
asthma, increased ASM mass cannot be completely abolished by current first line asthma 
treatments. Also, the available evidence suggests that the increase in ASM occurring during 
exacerbations and due to hypertrophy of ASM cells might be more prominent in large central than 
in small peripheral airways and can be reversed with treatment, at least partly. However, to which 
extent any available any pharmacological or biological treatment effectively reduces the number of 
ASM cells in the airways of asthmatic patients remains largely unknown.  
Most studies investigating the effect of corticosteroid treatment on airway remodeling in human 
patients have focused on changes of the bronchial extracellular matrix in endobronchial biopsy 
samples. It is now recognized that long-term high-dose corticosteroids treatment can decrease the 
basal membrane thickness in central asthmatic airways (Laitinen, et al., 1997, Olivieri, et al., 1997, 
Trigg, et al., 1994). However, this reversal is not observed in patients receiving low-dose treatment 
for the same length of time and showing a similar clinical improvement (Chetta, et al., 2003). 
Whether corticosteroids can also decrease the amount of ECM deposition within the lamina propria 
and to which extent in central and peripheral airways is less obvious. Endothelin, a protein involved 
in the process of lung repair and fibrosis, is increased in corticosteroid-naïve asthmatics compared 
to ICS-treated asthmatics and controls (Redington, et al., 1997). It has been reported that 2 weeks of 
oral corticosteroid did not reverse collagen deposition (Chakir, Shannon, Molet, Fukakusa, Elias, 
Laviolette, Boulet and Hamid, 2003), while a significant decrease was observed after 6 months of 
inhaled budesonide given at high dosage, modulated by tissue MMPs and TIMPs (Hoshino, et al., 
1999). On the other hand, a 2-year treatment with low-dose corticosteroids did was not successful at 
decreasing collagen deposition within the lamina propria in human asthma (Chakir, et al., 2010). 
Another study reported that neither short-term fixed dose nor long-term (< 6 months) treatment with 
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variable doses of inhaled steroids significantly altered the collagen content of the tissue (Godfrey, 
Lorimer, Majumdar, Adelroth, Johnston, Rogers, Johansson and Jeffery, 1995). The synthesis of 
ECM proteins is stimulated by TGF-β, which is increased in asthmatic airways and blood, and 
respiratory secretions (Halwani, et al., 2011). Corticosteroid treatment can partly decrease serum 
and sputum TGF-β expression in the long but not in the short-term (Chakir, Shannon, Molet, 
Fukakusa, Elias, Laviolette, Boulet and Hamid, 2003, Kai, et al., 2007, Kawayama, et al., 2008, 
Manuyakorn, et al., 2008); nevertheless, TGF-β levels remain higher in asthmatic patients 
compared to healthy subjects (Manuyakorn, Kamchaisatian, Atamasirikul, Sasisakulporn, 
Direkwattanachai and Benjaponpitak, 2008, Yamaguchi, et al., 2008). TGF-β expression within the 
bronchial wall is not affected by corticosteroid treatment at all (Tomkowicz, et al., 2008). Elastin is 
another ECM component possibly undergoing remodeling in asthma. However, corticosteroid 
treatment does not affect elastin content of the tissue in large airways (Bousquet, Lacoste, Chanez, 
Vic, Godard and Michel, 1996, Godfrey, Lorimer, Majumdar, Adelroth, Johnston, Rogers, 
Johansson and Jeffery, 1995). Overall, these findings suggest that airway fibrosis and ECM 
deposition is not directly targeted or effectively treated by corticosteroids alone in asthmatic 
patients. Although restricted to few studies, there is evidence that β2-agonists could modulate 
remodeling of the bronchial ECM in asthma when administered for an extended period of time. 
Twelve weeks of treatment with salbutamol reduced the tenascin but not the collagen content of the 
bronchial wall in biopsies from mild asthmatics (Altraja, et al., 1999), while only six weeks of 
salmeterol treatment but had no effect on the underlying remodeling processes despite improving 
the clinical indices of the disease (Roberts, et al., 1999). The recent and somehow surprising finding 
that bronchoconstriction itself can induce remodeling in asthmatic patients (Grainge, Lau, Ward, 
Dulay, Lahiff, Wilson, Holgate, Davies and Howarth, 2011) rises legitimate questions on whether 




In this context, asthmatic horses might be employed to investigate hypotheses that would be 
unethical in human subjects. We have recently shown that long term (3 months) treatment with 
salmeterol, a β2-adrenergic agonist, effectively reduced ECM remodeling in the equine model of 
asthma, albeit not controlling airway hyperresponsiveness or inflammation (Bullone, Vargas, Elce, 
Martin and Lavoie, 2017c). Further studies have shown a more marked effect in central than in 
peripheral airways concerning the inhibition of the deposition of ECM elements in the lamina 
propria of asthmatic horses (Bullone, Vargas, Elce, Martin and Lavoie, 2017c, Leclere, Lavoie-
Lamoureux, Joubert, Relave, Lanctot Setlakwe, Beauchamp, Couture, Martin and Lavoie, 2012a). 
Whether this was due to impaired deposition of the inhaled drugs at the peripheral levels of the 
bronchial tree or to different pathophysiological mechanisms sustaining remodeling will have to be 
elucidated. Studies in asthmatic patients and horses suggest that asthma-associated ECM 
remodeling, at least quantitatively, might be completely reversible by current pharmacological 
treatment if correctly addressed. It remains to be clarified whether the mechanical properties of the 
asthmatic airways in which remodeling has been reversed and of the healthy airways are the same.  
Few studies have investigated the effect of corticosteroid treatment on human bronchial epithelial 
structure or function in vivo, reporting an increased proliferation and a restitution of the epithelial 
thickness to normal values (Vignola, et al., 2001), joined to a  reduction of epithelial cells in BALF 
(Ward, et al., 2002). Also, a normalization of the ciliated to goblet cell ratio has been reported 
following inhaled corticosteroid treatment (Laitinen and Laitinen, 1995). In horses, unpublished 
data suggest that ICS treatment can reduce epithelial thickness, epithelial proliferation as well as 
goblet cell density in asthmatic horses (Bullone, et al., 2017a). However, these differences were not 
noticed when asthmatic horses in exacerbation and remission of the diseases were studied cross-
sectionally using semi-quantitative methods (Bullone, Helie, Joubert and Lavoie, 2016a).    
 
Determinants of airway remodeling 
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In order to study the effect that any intervention might induce on airway remodeling, additive 
effects due to inflammation and ASM contraction should ideally be separated or nullified. While 
preventing ASM contraction can be achieved by means of bronchodilators or spasmogens, 
inflammation can hardly be kept stable or nullified in human asthmatics.  
In this perspective, severe equine asthma offers a unique model where researchers are able to 
differently modulate inflammation and remodeling. Different studies have shown that BALF 
neutrophilia can be reversed only when the horse is removed from the offending environment (that 
is, only when exposure to the antigen mixture causing the exacerbation is stopped) for a prolonged 
interval of time (Bullone, Vargas, Elce, Martin and Lavoie, 2017c, Leclere, Lavoie-Lamoureux, 
Joubert, Relave, Lanctot Setlakwe, Beauchamp, Couture, Martin and Lavoie, 2012a). If this is not 
achieved, BALF neutrophilia is maintained while lung function and remodeling of the airways is 
improved (Bullone, Vargas, Elce, Martin and Lavoie, 2017c, Leclere, Lavoie-Lamoureux, Joubert, 
Relave, Lanctot Setlakwe, Beauchamp, Couture, Martin and Lavoie, 2012a), providing a rare 
opportunity to study remodeling in the presence vs. absence of BALF neutrophilic inflammation. 
The same reasoning can be repeated using selected bronchodilators (with more or less pronounced 
anti-inflammatory properties) and other anti-inflammatory drugs. The limitation of this approach is 
that it is restricted to the neutrophilic inflammatory processes detected in equine BALF, and it is not 
known to what extent it reflects what happens in the airway wall. The available information using 
this model suggests that bronchial wall inflammation is modulated differently by treatment at the 
central and peripheral levels of the bronchial tree. Indeed, while even a short-term treatment with 
corticosteroids reduces inflammatory cell counts in the submucosa of the large airways, no such 
effect is detected in peripheral airways (Bullone, 2016, Leclere, Lavoie-Lamoureux, Joubert, 
Relave, Lanctot Setlakwe, Beauchamp, Couture, Martin and Lavoie, 2012a).      
 
Strengths and limitations of the model 
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Due to the spontaneous occurrence of disease, their long lifespan and large dimensions, horses are 
well-suited models for human asthma. Main physiopathological differences between species are the 
lack of a predominant eosinophilic signature in the severe form of equine asthma, the increased 
thickness of the lamina propria – rather than a thinning as reported in severe human asthma (Pepe, 
Foley, Shannon, Lemiere, Olivenstein, Ernst, Ludwig, Martin and Hamid, 2005), and the major 
involvement of small (<2 mm in diameter) rather than large airways in equine asthma. In this 
perspective, horses might, however, represent a well-suited model for studying non-eosinophilic 
human asthma. Also, horses might be a more suitable model for studying peripheral rather than 
central airway remodeling. Indeed, even the largest bronchi in men reach dimensions of 
approximately 1-1.5 cm (Montaudon, et al., 2007, Zahedi-Nejad, et al., 2011), which correspond to 




 generation in a 500 kg adult horse, considering its 
monopodial branching scheme. This anatomic difference could lead to different structure-function 
relationship in the two species when considering large airways. Furthermore, the central airways are 
easily accessible in humans, decreasing the need of an animal model to study changes occurring at 
this level of the airways. 
Equine asthma model is not free from limitations. First of all, there are practical limitations such as 
the need of large dedicated facilities, personnel and equipment; the fact that asthmatic horses must 
be looked for and recruited from animal owners, and cannot be “produced on demand”. Moreover, 
working with the equine model of asthma requires employing many products, devices and 
instruments that are not developed for the use in horses. This requires their adaptation to this 
species and additional efforts. The availability of horse-adapted devices will grow only 
proportionally to its use in asthma research. On the other hand, to maximize the translational yield 
of this model, increased commitment is required by equine asthma scientists towards the 
improvement of the phenotyping/endotyping process of equine asthma, based (at least initially) on 
human knowledge. Having this information available could foster the preclinical research on 
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biologics as well. To these aims, the question on whether large scale/multi-centric epidemiological 
studies need to be implemented in asthmatic horses remains open and deserves future attention.  
 
Conclusions 
In summary, equine asthma provides a spontaneous model of asthma-associated airway remodeling 
which closely resemble that occurring in human asthma especially at the level of the small 
peripheral airways. Given the paucity of information on the effect of many asthma therapies on 
airway remodeling, and the growing interest in this field by human asthma researchers, equine 
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Figure 1. Bronchial section from a non-asthmatic (A) and from an asthmatic horse (B). Bronchial 
remodeling in equine asthma closely resembles what is observed in human asthmatics. Structural 
alterations are visible in the right panel affecting the smooth muscle layer as well as the adventitia 
and lamina propria, all thickened and markedly rearranged. In equine asthma, is also appreciable the 
increased presence of mucus (green) within the airway lumen, at this level of the bronchial tree 
mainly produced by metaplastic bronchial epithelial cells. Histologic sections were stained with 





Figure 2. Terminology used in the scientific literature to define the asthma-like disease affecting 
adult horses (modified from (Bullone, 2018)).  
 
